Abstract
BackgroundAnti-tumor necrosis factor (TNF) therapy is recommended when conventional DMARDs therapy fails to decrease disease activity of rheumatoid arthritis (RA) to at least low disease activity. One of the advantages...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
